The analyst recommends the iShares Biotechnology ETF (IBB) as a way to gain exposure to the high-growth biotech sector without the difficulty and risk of picking individual stocks. Given the volatility and specialized knowledge required for biotech stock selection, IBB offers diversification across over 250 companies, from large caps like Vertex and Gilead to smaller firms, providing a safer entry point into this fast-growing healthcare segment.
“So, without that industry experience, you're setting yourself up for 20 or 30% swings in a stock price when that testing news comes out. And it's not always in the direction you want. Now, this doesn't necessarily mean you avoid the biotech stocks because this is the fastest growth in healthcare, but it does mean that you buy a broader fund like the IBB instead of trying to pick individual winners.”